Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy

Study Overview
=================
Brief Summary
-----------------
The study is designed as non interventional to collect data on the effectiveness of acarbose and metformin monotherapy, respectively, in terms of change from baseline in post prandial blood glucose level at the end of 16 weeks in drug-naïve type 2 diabetic patients within each carbohydrates consumption subgroup under real-life treatment condition in large sample of type-2 diabetes patients in India. The study will begin after the study approval by ethics committee.All drug naïve patients in whom decision to administer acarbose or metformin monotherapy for type 2 diabetes management has been made will be included in study after taking the informed consent.Patients will be observed for up to 16 weeks (2 weeks).The study involves general examination of patients, collection of data like history of disease, concomitant medication, drug dose , 24 hr dietary recall etc. The study is planned to enroll 12250 subjects from multiple study centers spread across India. The study data will be analyzed with appropriate statistical methods.

Official Title
-----------------
Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: Bay G5421 Glucobay
* Drug: Metformin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Drug-naïve (i.e., the patients should never be treated with anti-diabetic drugs before screening) patients in whom decision to administer monotherapy with either acarbose or metformin for type-2 diabetes management has been made by the attending physician on the basis of best clinical practice and medical patient needs, and who consent to participate in study will be included Exclusion Criteria: Patients receiving any anti-diabetic medication at the time of enrollment in the study will be excluded. However, during observation period, patients may receive any additional anti-diabetics medication at the decision of investigator. Exclusion criteria should be read in conjunction with local product information. All contra-indications according to the local marketing authorization should be considered

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>Acarbose_BAY G5421 | Drug: Bay G5421 Glucobay<br>* Oral, dosage of Acarbose as per the directions of treating physician<br>|
| Group 2<br>Metformin | Drug: Metformin<br>* Oral, dosage of Metformin as per the directions of treating physician<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The mean change in post-meal glucose levels from baseline at the end of observation period of up to 16 weeks | The primary outcome will be summarized separately in acarbose and metformin monotherapy treated patients having carbohydrates consumption (National Institute of Nutrition (NIN), India recommend50% to 60% of total calories from carbohydrates in balance diet : - Below NIN recommendation (< 50%) - As per NIN recommendation (50% to 60%) - Above NIN recommendation (> 60%) | baseline and 16 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean change of HbA1c |  | Baseline and 16 weeks | 
| Mean change of fasting blood glucose(FBG) |  | Base line and 16 weeks | 
| Mean change of low density lipoprotein cholesterol(LDL) |  | baseline and 16 weeks | 
| Mean change of high density lipoprotein cholesterol(HDL) |  | Baseline and 16 weeks | 
| Mean change of total cholesterol(TC) |  | baseline and 16 weeks | 
| Mean change of Body weight |  | baseline and 16 weeks | 
| Mean change of triglyceride(TG) |  | baseline and 16 weeks | 
| Compare the mean change between acarbose and metformin arm of postprandial blood glucose (PPBG) |  | baseline and 16 weeks | 
| Compare the mean change between acarbose and metformin arm of HbA1c |  | baseline and 16 weeks | 
| Compare the mean change between acarbose and metformin arm of FBG |  | baseline and 16 weeks | 
| Compare the mean change between acarbose and metformin arm of LDL |  | baseline and 16 weeks | 
| Compare the mean change between acarbose and metformin arm of HDL |  | baseline and 16 weeks | 
| Compare the mean change between acarbose and metformin arm of TC |  | baseline and 16 weeks | 
| Compare the mean change between acarbose and metformin arm of TG |  | baseline and 16 weeks | 
| Compare the mean change between acarbose and metformin arm of Body weight |  | baseline and 16 weeks | 
| Change in gastrointestinal tolerability to therapy from post baseline visit to the end of observation period of up to 16 weeks |  | baseline and 16 weeks | 
| Incidence rate of adverse drug reactions in acarbose and metformin treated groups during 16 weeks observation period |  | 16 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Type 2 Diabetes